Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celgene Cp Cvr (CELGZ)

Celgene Cp Cvr (CELGZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.40 +17.48%
on 11/20/19
0.53 -11.34%
on 10/31/19
unch (-0.02%)
since 10/29/19
3-Month
0.40 +17.48%
on 11/20/19
1.24 -62.10%
on 09/26/19
-0.08 (-14.58%)
since 08/29/19
52-Week
0.35 +34.26%
on 12/28/18
1.65 -71.52%
on 03/12/19
-0.42 (-47.20%)
since 11/28/18

Most Recent Stories

More News
Global Targeted Protein Degradation Market (2020 to 2030) - Featuring Radius Health, Celgene and Sanofi Genzyme Among Others

The "Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

CELGZ : 0.47 (+2.15%)
RDUS : 19.36 (-3.01%)
Amgen Canada Receives Approval of Marketing Authorization Transfer of OTEZLA® for the Treatment of Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

Addition of OTEZLA Strengthens Amgen's Long-Standing Expertise in Inflammation

AMGN : 222.79 (+0.29%)
CELGZ : 0.47 (+2.15%)
Regenerative Medicine Market Analysis Report 2026 | Global Market Size, Trends, Growth, Statistics, Insights and Forecast.

The global Regenerative Medicine Market size projected to reach USD 151,949.5 million by the end of 2026. Product applications in the treatment of chronic diseases will provide impetus to market growth....

CRYO : 0.3400 (+19.30%)
CELGZ : 0.47 (+2.15%)
MDT : 113.28 (-0.51%)
WMGIZ : 0.01 (unch)
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019

Bristol-Myers Squibb Company (NYSE:BMY) today reports results for the fourth quarter and full year of 2019, which highlight continued strong sales and robust operating performance, along with the ongoing...

CELGZ : 0.47 (+2.15%)
BMY : 65.63 (+0.71%)
FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb

--Bristol-Myers Squibb initiates Phase 1B clinical trial in patients with advanced or unresectable solid tumors for FORMA-discovered, Celgene-licensed pan BET inhibitor CC-95775

CELGZ : 0.47 (+2.15%)
BMY : 65.63 (+0.71%)
Evotec And Bayer Advance Further Programme Into Phase I Clinical Development

HAMBURG, GERMANY / ACCESSWIRE / January 30, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its partner Bayer AG has decided to advance a further...

BAYRY : 20.0699 (-0.79%)
CELGZ : 0.47 (+2.15%)
EVTC : 33.31 (-3.45%)
NVS : 96.76 (+0.49%)
NVO : 63.85 (+0.54%)
Century Therapeutics Expands Board of Directors and Management Team

Century Therapeutics, a Versant Ventures-founded developer of next-generation allogeneic cell therapies, today announced the appointments of Joseph Jimenez to its board of directors and Greg Russotti,...

CELGZ : 0.47 (+2.15%)
NVS : 96.76 (+0.49%)
Neuroendocrine Carcinoma Market is projected to grow at a high 7.7% CAGR throughout 2017-2027

Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions...

AMGN : 222.79 (+0.29%)
CELGZ : 0.47 (+2.15%)
CHMA : 4.60 (+1.32%)
HCM : 26.19 (-4.59%)
LXRX : 2.69 (-5.61%)
NVS : 96.76 (+0.49%)
TEVA : 13.19 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Eosinophilic Esophagitis, Pipeline Review, H2 2019 - Adare Pharmaceuticals Inc, Celgene Corp, Kyowa Kirin Co. Inc & Quorum Innovations LLC - ResearchAndMarkets.com

The "Eosinophilic Esophagitis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

CELGZ : 0.47 (+2.15%)
Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial

APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead...

AGIO : 53.11 (-1.06%)
ALXN : 103.14 (+0.59%)
ALPMF : 17.0200 (-0.93%)
CELGZ : 0.47 (+2.15%)
GILD : 69.70 (+4.03%)
APVO : 0.48 (-2.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CELGZ with:

Business Summary

N/A

See More

Key Turning Points

2nd Resistance Point 0.50
1st Resistance Point 0.49
Last Price 0.47
1st Support Level 0.45
2nd Support Level 0.42

See More

52-Week High 1.65
Fibonacci 61.8% 1.15
Fibonacci 50% 1.00
Fibonacci 38.2% 0.85
Last Price 0.47
52-Week Low 0.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar